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Introduction. Cardiovascular (CV) diseases are a major cause of death in rheumatoid arthritis (RA) patients. Novel biomarkers
[B-type natriuretic peptide (BNP); osteoprotegerin (OPG)/receptor activator of nuclear factor-kappa B ligand (RANKL) ratio;
and dickkopf-1 (DKK-1)] have been used in CV risk assessment. We analysed, in established RA patients, the presence of silent
myocardial ischemia and its association with clinical variables, BNP, and bone and atheroma biomarkers.Methods. From a single-
center tertiary referral hospital, RA patients asymptomatic for CV disease were submitted to myocardial perfusion scintigraphy
(MPS) under adenosine stress and biomarkers measurements. Logistic regression was used to estimate crude odds ratios (OR)
and 95% confidence intervals (CI). Results. In 189 patients, perfusion defects were frequent (25%) and associated with BNP ≥
100 pg/mL (OR = 5.68; 95% CI: 2.038–15.830), fourth log OPG/RANKL ratio quartile (OR = 2.88; 95% CI: 1.091–7.622), and DKK-
1 ≥ 133 pmol/L (OR = 2.69; 95% CI: 1.058–6.840). Similar associations were confirmed in those with C-reactive protein > or ≤
3mg/L. No relationship was found with the majority of traditional CV factors nor with disease variables. Conclusions. Our results
corroborated the hypothesis that MPS could reveal subclinical CV dysfunction, supported the utility of BNP measurements as a
screening tool, and put in perspective the potential usefulness of complementary approaches in CV risk assessment in RA patients.
1. Introduction
Cardiovascular diseases (CVD) are a major cause of death
in rheumatoid arthritis (RA) patients [1] and clinical events
occur approximately 10 years earlier than in the general
population [2].The pooled relative risk of CVD is near 1.5 [3]
and cardiac risk is similar to that of type 2 diabetes mellitus
(T2DM), especially in RA patients with long disease duration
[4].
The CV risk increases in ongoing disease but is already
higher than in non-RA subjects at the time of RA diagnosis
[5]. The risk seems to be less associated with the traditional
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(arterial hypertension, diabetes, dyslipidemia, and obesity) or
other known CV risk factors (hyperuricemia, hyperhomo-
cysteinemia, and vitamin D deficiency) and more with the
disease itself (inflammatory and autoimmune mechanisms)
and therapeutic related variables [6]. The relationships with
and between each risk factor are complex and have been
progressively unraveled in recent years [6].
Considering the increased risk, the EUropean League
Against Rheumatism (EULAR) recommends annual CV risk
assessment in RA patients (or every 2 to 3 years, if low
CV risk and inactive disease occur) [7], with calculation
of a modified SCORE index based on traditional CV risk
factors, multiplied by 1.5 in the presence of 2 out of 3 RA
factors: disease duration > 10 years, certain extra-articular
manifestations, or positivity for rheumatoid factor (RF) or
anti-cyclic citrullinated peptides (anti-CCP) antibodies.
However, there are uncertainties about the effectiveness
of this method in individual CV risk appraisal [5]. In line,
several authors have pointed out the need for complemen-
tary approaches, including CV imaging techniques and the
quantification of newly available biomarkers [8–10].
Myocardial perfusion scintigraphy (MPS) is an imaging
method robustly validated in CV risk assessment in several
categories of patients [11].
On the other hand, in recent years, new biomarkers that
can reflect the interplay between inflammation, atheroscle-
rosis, and plaque instability phenomena have been tested
on clinical grounds and some seem promising in CV risk
estimation. Serum B-type natriuretic peptides have been
clearly associated with CV death and, in RA patients, with
CVand generalmortality [9]. Less data and conflicting results
still exist in what regards the association between another
group of mediators, such as osteoprotegerin (OPG) [10], the
receptor activator of nuclear factor-kappa B ligand (RANKL)
[12], or dickkopf-1 (DKK-1) [13], and the development of
CVD in RA.
In this study we included MPS in our risk stratification
protocol of patients with established RA. We aimed to eval-
uate the prevalence of myocardial perfusion defects and to
relate theMPS results with various clinical features, including
disease characteristics, therapy, traditional CV risk factors,
and serum biomarkers [B-type natriuretic peptide (BNP),
OPG, RANKL, DKK-1, and sclerostin].
2. Patients and Methods
2.1. Rheumatoid Arthritis Patients. During a six-month
period, patients with RA, classified according to the 1987
American College of Rheumatology criteria [14] and asymp-
tomatic for cardiac disease (angina or heart failure signs
and symptoms), were prospectively included in the study
protocol. In this time-frame, a total of 216 RA patients were
eligible, although only 189 accepted to perform MPS.
The exclusion criteria were history of previous ischemic
heart disease, presence of angina, heart failure, or Q waves on
basal electrocardiogram (ECG).
Through a rheumatology appointment, all subjects
underwent clinical assessment using the Portuguese version
of the StanfordHealth Assessment Questionnaire (HAQ) and
the Disease Activity Score (DAS28) four variables (4v) [15],
the most commonly used tools in daily clinical practice to
determine the RA disease activity. All data regarding past
and ongoing prescribed medications, including NSAIDs and
corticosteroids exposure time, were obtained from medical
records review. Corticosteroids daily dose was the one at the
study inclusion time.
Hypertension, diabetes, and dyslipidemia were defined
by self-reporting and contemporary use of compatible med-
ications and/or clinical data assessment in previous medi-
cal registries. Office blood pressure (>140/90mmHg), lipid
profile (total cholesterol > 200mg/dL), and fasting plasma
glucose (<126mg/dL) were categorized according to the
European guidelines. The smoking status (past and current)
was registered and the body mass index (BMI) calculated.
2.2. Laboratory Measurements. Between 08:00 and 10:00
hours in the morning, a fasting blood sample was collected
to evaluate the lipid profile [high-density lipoprotein (HDL)
cholesterol, low-density lipoprotein (LDL) cholesterol, total
cholesterol (TC), triglycerides, lipoprotein (a), apolipopro-
tein A1 (ApoA1), and apolipoprotein B (ApoB)], as well as
glucose and insulin, C-reactive protein (CRP), erythrocyte
sedimentation rate (ESR), RF and anti-CCP antibodies,
homocysteine, uric acid, 25(OH) vitamin D3, parathyroid
hormone, osteocalcin, BNP, OPG, RANKL, DKK-1, and scle-
rostin levels. Serum samples were stored at −70∘C for OPG,
RANKL, DKK-1, and sclerostin measurements by ELISA.
All these specimens were measured in duplicate, according
to the manufacturer’s instructions and then averaged. OPG
and DKK-1 were determined using kits from BIOMEDICA
immunoassays (Vienna, Austria); the intra-assay coefficients
of variation (aCV) were ≤3% for both; the inter-aCV was
≤3% for DKK-1 and between 3 and 5% for OPG. RANKL was
determined using a kit from CUSABIO (Wuhan, China); the
intra-aCV was <8% and the inter-aCV was <10%. Sclerostin
was determined using a kit from TECO (Sissach, Switzer-
land); the intra- and inter-aCVs were 3.8–8.0% and 3.3–9.0%,
respectively.
2.3. Myocardial Perfusion Scintigraphy. For minimization
of exposure to radiation, all patients underwent a routine
procedure used in our institution of adenosine-stress single
photon emission-computed tomography (SPECT) myocar-
dial perfusion imaging, in a one-day protocol, with the use
of stress-first imaging protocol. Images at rest were only
acquired if any perfusion defects were detected after the
stress phase. This protocol implies the injection of 10 (at
stress) to 30 (at rest) mCi doses of TC-99m tetrofosmin,
adenosine infused at a rate of 140 𝜇g/kg/min over 6min, and
radiopharmaceutical administration at 3min of adenosine
perfusion.
SPECT imaging was acquired in a Gamma Camera
Infinia Hawkeye, GE Healthcare, 15–30min after radiophar-
maceutical administration.
The SPECT images were interpreted in a blinded fashion,
by two experienced physicians, consecutively during the
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study protocol, interspersed with other MPS in patients
without RA. Bearing in mind the female predominance [16,
17] attenuation correction (AC) was applied on a case by
case basis, depending on patient BMI (≥30 kg/m2) and breast
volume, using an integrated computed tomography (CT)
scanner. A 3 min low-dose CT scan (140 keV, 2.5mAs) was
acquired at the end of stress and rest acquisitions.
Myocardial perfusion was assessed through expert visual
analysis in a 17 left ventricle (LV) segmentation model.
QGS/QPS software was used to quantify the extension and
severity of perfusion defects, wall motion andwall thickening
scores, LV end-diastolic and end-systolic volumes (EDV and
ESV), and ejection fraction (EF).
Myocardial perfusion was considered abnormal only if
the summed stress score (SSS) was ≥4. Perfusion defects
were classified as mild (SSS ≥ 4 and ≤8), moderate (SSS > 8
and ≤13), or severe (SSS > 13) and myocardial ischemia was
considered significant if the summed difference score (SDS)
with respect to MPS at rest was ≥4 [18].
2.4. Ethics. Informed consent was obtained from each
patient.The study protocol conforms to the ethical guidelines
of the 1975 Declaration of Helsinki as reflected in a priori
approval (on March 13, 2008) by the institution’s human
research committee.
2.5. Follow-UpData. All patients were followed during a five-
year period. Death and CV events, including the onset of
cardiac symptoms, were registered.
2.6. Statistical Analyses. Qualitative data are described as
absolute counts and proportions and quantitative data as
mean (standard deviation). CRP, ESR, and OPG/RANKL
ratio were log-transformed to obtain symmetrical distribu-
tions. The magnitude of the associations between clinical
and laboratory variables and the presence of defects in MPS
were assessed using logistic regression models in order to
estimate crude odds ratios (OR) and their 95% confidence
intervals (CI). All analyses were two-sided and 𝑝 values <
0.05 were considered statistically significant. Since this study
was oriented by a priori defined hypotheses no adjustments
for multiple comparisons were conducted, as supported by
previous literature [19]. Statistical analyses were performed
using STATA software V.11 (Statacorp, College Station, Texas,
USA).
3. Results
3.1. Patients Characteristics. One hundred and eighty-nine
patients with RA were included, with a mean age of 53 ±
12 years, the majority (𝑛 = 153, 81%) females. Disease
duration, measured from the date of diagnosis, was 14 ±
10 years. The majority of patients presented erosive disease
(𝑛 = 187, 99%) and were seropositive for RF (𝑛 = 115,
61%) and anti-CCP (𝑛 = 152, 80%) antibodies. The mean
DAS28 (4v) and HAQ were 4.266 ± 1.324 and 1.275 ±
0.708, respectively. DAS28 remission was present in 18 (10%)
patients. Extra-articular manifestations were present in 67
(35.4%) patients: Sjo¨gren syndrome (20%), rheumatoid nodes
(16%), interstitial lung disease (3%), AA amyloidosis (3%),
scleritis (3%), and rheumatoid vasculitis (2%).
Clinical and laboratory variables are shown in Table 1.
3.2. Relation of Myocardial Perfusion Scintigraphy Findings
with Clinical and Laboratory Parameters. On basal ECG, 184
(97%) patients were in sinus rhythm and 5 (3%) had left
bundle branch blockage (LBBB).
MPS showed myocardial perfusion defects (SSS ≥ 4) in
47 (25%) patients, mild defects in 35 (18.5%), moderate in 10
(5.3%), and severe in 2 (1%).Thedefects had amean SDS of 4.1
± 3 and stress extension of 2.5 ± 3.6% and were reversible at
rest in 31 (16%) cases. LV ejection fraction (LVEF)was inferior
to 45% in 9 (4.76%) patients with amean value of 63.7 ± 9.8%.
The perfusion defects were either unique (25/47, 53%)
or multiple (22/47, 47%), with no preferential distribution at
different coronary territories.
Figure 1 illustrates an abnormalMPS in female RApatient
without any cardiac symptom.
On logistic regression analysis, no relationship was found
between the presence of myocardial perfusion defects and
patient age, gender, RA disease or therapy related features,
smoking habits, history of dyslipidemia, diabetes, or hyper-
tension, neither with determinations, at inclusion protocol,
of serum levels of lipids, glucose, or insulin. MPS findings
were associated with BMI (OR = 1.120; 𝑝 = 0.002), therapy
with ARAs (OR = 2.471; 𝑝 = 0.046), diuretics (OR = 2.195;
𝑝 = 0.045), and oral antidiabetic (OR = 3.031; 𝑝 = 0.033),
as well as with circulating levels of BNP ≥ 100 pg/mL (OR
= 5.680; 𝑝 = 0.001), DKK-1 ≥ 133 pmol/L (OR = 2.690;
𝑝 = 0.038), and fourth log OPG/RANKL ratio quartile (OR
= 2.884; 𝑝 = 0.033) (Table 2).
In a subgroup analysis of thosewhopresentedCRPhigher
than 3mg/L (upper limit of normality for our laboratory), we
found the same associations with similar magnitudes, except
for ARAs and diuretics use. MPS findings were associated
with BMI (OR = 1.174; 𝑝 = 0.001), oral antidiabetics (OR =
3.840; 𝑝 = 0.017), levels of BNP ≥ 100 pg/mL (OR = 5.610;
𝑝 = 0.004), DKK-1 ≥ 133 pmol/L (OR = 3.142; 𝑝 = 0.056),
and fourth log OPG/RANKL ratio quartile (OR = 2.410; 𝑝 =
0.001).
3.3. Follow-Up Data: Cardiovascular Events. During a period
of 5 years, 9 patients deceased, 2 from CV causes: two
sudden cardiac deaths, one of them after an acute myocardial
infarction (MI) (confirmed by autopsy). In these two male
patients, LVEF was inferior to 45% and both presented
perfusion defects on MPS.
Apart from the CV deaths, three other patients developed
CV events. A male patient, with LBBB without perfusion
defects and with normal LVEF, had MI four years after MPS
evaluation. A female patient, with a mild perfusion defect
and normal LVEF, developed angina and was submitted to
percutaneous stent implantation in the anterior descendent
coronary artery. Another female patient, without perfusion
defects and with normal LVEF, had a stroke four years after
MPS evaluation. All these 5 patients with CV events were
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Table 1: Clinical and laboratory variables of the rheumatoid arthritis sample enrolled in the study.
Characteristic Value
Patient related
Female, 𝑛 (%) 153 (81.0)
Postmenopausal, 𝑛 (%) 59 (31.2)
Time since menopause, mean (SD), years 7.330 (8.275)
Age, mean (SD), years 53.340 (11.502)
BMI, mean (SD), kg/m2 27.150 (4.768)
Ever smokers, 𝑛 (%) 24 (12.7)
Hypertension, 𝑛 (%) 39 (20.6)
Diabetes mellitus, 𝑛 (%) 14 (7.4)
Dyslipidemia, 𝑛 (%) 23 (12.2)
Disease related
Disease duration, mean (SD), years 13.72 (9.955)
RF positivity, 𝑛 (%) 115 (60.847)
Anti-CCP antibodies positivity, 𝑛 (%) 152 (80.423)
DAS28 (4V), mean (SD) 4.266 (1.324)
Remission (DAS28 (4v) < 2.6) 18 (9.5)
Low (2.6 < DAS28 (4v) ≤ 3.2) 27 (14.3)
Moderate (3.2 < DAS28 (4V) ≤ 5.1) 95 (50.3)
High (DAS28 (4v) > 5.1) 49 (25.9)
ESR, mean (SD), mm (first hour) 27.100 (20.603)
CRP, mean (SD), mg/L 11.573 (20.045)
Global health on VAS, mean (SD) 44.190 (17.794)
HAQ score, mean (SD) 1.275 (0.708)
RA related treatment
Corticosteroids, 𝑛 (%) 155 (82.0)
Daily dose in prednisolone equivalents, mean (SD), mg 5.139 (3.977)
Time under corticosteroids, mean (SD), years 11.429 (8.981)
NSAIDs, 𝑛 (%) 142 (75.1)
DMARDS, 𝑛 (%) 160 (84.7)
Cumulative, mean (SD) 2.534 (1.416)
Time under DMARDs, mean (SD), months 104.037 (87.714)
Methotrexate, 𝑛 (%) 130 (68.8)
Leflunomide, 𝑛 (%) 40 (21.1)
Biologic DMARDs, 𝑛 (%) 97 (51.3)
Time under biologics, mean (SD), months 60.258 (30.080)
Anti-TNF𝛼 blockers, 𝑛 (%) 83 (43.9)
Non-anti-TNF𝛼 blockers, 𝑛 (%) 14 (7.4)
Bisphosphonates, 𝑛 (%) 69 (36.5)
Cardiovascular related treatment
Antiaggregants, 𝑛 (%) 22 (11.6)
ACEIs, 𝑛 (%) 24 (12.7)
ARAs, 𝑛 (%) 24 (12.7)
CCAs, 𝑛 (%) 18 (9.5)
BBs, 𝑛 (%) 15 (7.9)
Diuretics, 𝑛 (%) 37 (19.6)
Warfarin, 𝑛 (%) 5 (2.6)
Statins, 𝑛 (%) 45 (23.8)
Oral antidiabetic agents, 𝑛 (%) 17 (9.0)
Insulin, 𝑛 (%) 5 (2.6)
ACEIs, angiotensin converter enzyme inhibitors; ARAs, angiotensin receptor antagonists; BBs, beta-blockers; BMI, body mass index; CCAs, calcium channel
antagonists; CCP, cyclic citrullinated peptides; CRP, c-reactive protein; DAS, disease activity score; DMARDS, disease-modifying antirheumatic dugs; ESR,
erythrocyte sedimentation rate; HAQ, health assessment questionnaire; NSAIDs, nonsteroidal anti-inflammatory drugs; RF, rheumatoid factor; SD, standard
deviation; TNF𝛼, tumour necrosis factor alpha; VAS, visual analogic scale.
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Figure 1: Moderate and reversible anteroseptal perfusion defect compatible with ischemia in the left anterior descending coronary artery
territory in an asymptomatic female RA patient.
seropositive for RF and anti-CCP antibodies, were nonobese,
and had low to moderate disease activity by DAS28 and a
normal BNP value at baseline and at least one traditional CV
risk factor under treatment.
4. Discussion
The major finding of this study comprised the description
of myocardial perfusion scintigraphy findings in a large RA
patient sample, characterized by a long disease duration, with
moderate activity, and with no apparent cardiac symptoms.
The relationship ofMPS results with several clinical variables,
including traditional CV risk factors and novel biomarkers of
atherosclerosis, was also evaluated.
RA is characterized by earlier atherosclerosis and CV
events in comparison with the general population [2, 20].
Overall, the pooled relative risk is 1.68 and 1.87 formyocardial
infarction and congestive heart failure (HF), respectively
[3]. Myocardial ischemia is often asymptomatic and clinical
detection is frequently made at an advanced stage. HF is a
major cause ofmorbidity andmortality in RA, accounting for
about 20% of mortality in patients with RA [21]. The risk of
HF has been associated with RF positivity, ESR, severe extra-
articular involvement, and steroids use [22].
As most CV events are of cardiac origin, it seems
appropriate to consider the integration of cardiac imaging
in primary prevention strategies, at least in the highest
risk patients. However we have few clinical tools able to a
priori identify these patients and, until now, few studies have
assessed the presence of silent ischemia in large RA patients
populations [23].
MPS is a robustly validated risk stratification method in
different populations, and a normal MPS is associated with
≤1%/year combined mortality and nonfatal infarction rate
[24]. It is a noninvasive functional test that depends not only
on the presence of epicardial coronary stenosis (macrovas-
cular disease) but also on the endothelial function, including
in the small vessels territories (microvascular disease), which
may be early affected during disease development and can be
modulated by the inflammatory state.
It is important to note that the nature of the perfusion
defects can have an ischemic/atherosclerotic etiology but
could also result from other causes like cardiac amyloidosis
[8] or interstitial fibrosis. The clinical impact of discriminat-
ing the different causes of perfusion defects, for instance, by
cardiac magnetic resonance is still unknown.
No relationship was found between the MPS results and
the classic CV risk factors. The lack of associations could
be explained by the well-known complex interplay between
inflammation and therapy that could alter the link between
risk factors and atherosclerosis manifestations, as already
pointed by other authors [25].
The fact that in our patients we did not find relations
between MPS results and the traditional risk factors can thus
be explained by the fact that the usual relationships were
changed by the inflammatory RA disease activity and/or by
medications such as with nonbiologic (85%) or biological
(51%) DMARDs.
ESR and CRP levels are related to disease activity and
inflammation; seropositivity also increases CV risk in RA
patients [26]. On the other hand, high CRP levels are related
to an increased intima media thickness [27] and baseline
values also predict accelerated brachial arterial wall changes
in patients with recent-onset RA [28].
In our study, the presence of perfusion defects on MPS
was not related to systemic inflammatory markers (CRP and
ESR), nor with the presence of RF and anti-CCP antibodies
or DAS28 score.
The inflammatory state could have changed over time,
especially under therapy, and, later in disease progression, it
could be difficult to relate a unique plasma level (mean CRP
value of 11.57 ± 20.0mg/L in our patients) with the extension
of a long lasting process of cardiac damage.
B-type natriuretic peptides (BNP and NT-proBNP) are
independent predictors of CV morbidity and of all causes of
mortality including in RA patients.
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Table 2:Crude odds ratios for the associations between rheumatoid arthritis patients’ characteristics and the presence ofmyocardial perfusion
defects obtained by logistic regression analysis.
95% CI for OR
OR Lower Upper 𝑝 value
Male sex (versus female) 1.009 0.436 2.334 0.984
Age (per year) 1.000 0.971 1.029 0.989
Disease duration (per year) 1.013 0.981 1.047 0.435
BMI (per kg/m2) 1.120 1.044 1.202 0.002
Ever smoker (versus never smoker) 1.008 0.375 2.711 0.987
Smoking exposure (per year) 1.002 0.918 1.093 0.971
Time under biologics 1.002 0.993 1.010 0.729
DAS28 (4v) (per unit) 0.913 0.710 1.176 0.482
HAQ (per unit) 0.930 0.582 1.485 0.760
log CRP (per unit) 1.129 0.872 1.464 0.357
log ESR (per unit) 0.896 0.562 1.428 0.644
BNP (pg/mL)
<30 Reference Reference Reference Reference
≥30 and <100 1.635 0.780 3.428 0.193
≥100 5.680 2.038 15.830 0.001
Insulin resistance
<1 Reference Reference Reference Reference
≥1 and <1.5 2.260 0.816 6.263 0.117
≥1.5 and <2.5 1.361 0.500 3.707 0.546
≥2.5 1.005 0.322 3.135 0.994
TC/HDL ratio (per unit) 0.987 0.704 1.386 0.941
LDL/HDL ratio (per unit) 0.980 0.643 1.495 0.927
ApoB/ApoA1 ratio (per unit) 0.400 0.066 2.424 0.319
TC (per mg/dL) 0.935 0.368 2.377 0.888
LDL (per mg/dL) 0.952 0.295 3.070 0.934
HDL (per mg/dL) 1.005 0.103 9.801 0.996
TGs (per mg/dL) 1.338 0.774 2.314 0.297
ApoA1 (per mg/dL) 1.004 0.992 1.016 0.508
ApoB (per mg/dL) 0.995 0.980 1.010 0.526
Lp(a) (mg/dL) (per unit) 0.985 0.969 1.002 0.076
Uric acid (per mg/L) 1.010 0.989 1.032 0.359
Homocysteine (per 𝜇mol/L) 1.013 0.931 1.103 0.757
25(OH) vitamin D3 (per ng/mL) 1.023 0.998 1.048 0.077
Osteocalcin (per ng/mL) 1.010 0.968 1.054 0.651
DKK-1 (pmol/L) (per unit) 1.010 1.002 1.017 0.010
<60 Reference Reference Reference Reference
≥60 and <90 0.778 0.263 2.297 0.649
≥90 and <133 1.657 0.630 4.355 0.306
≥133 2.690 1.058 6.840 0.038
Sclerostin (per ng/mL) 2.071 0.063 68.436 0.683
log OPG/RANKL (per unit) 1.667 1.106 2.513 0.015
First quartile Reference Reference Reference Reference
Second quartile 1.357 0.481 3.828 0.564
Third quartile 1.537 0.553 4.268 0.410
Fourth quartile 2.884 1.091 7.622 0.033
Osteoprotegerin (per pmol/L) 1.161 0.987 1.366 0.072
RANKL (per pmol/L) 0.999 0.999 1.000 0.111
Prednisolone (mg a day) (per unit) 1.066 0.984 1.154 0.119
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Table 2: Continued.
95% CI for OR
OR Lower Upper 𝑝 value
Corticosteroid therapy duration (years) (per unit) 1.010 0.974 1.047 0.588
Methotrexate (mg once a week) (per unit) 0.992 0.952 1.034 0.713
NSAIDs use (current versus not current) 0.823 0.391 1.737 0.610
Bisphosphonates use (ever versus never) 0.671 0.330 1.365 0.271
ACEIs use (current versus not current) 1.615 0.643 4.060 0.308
ARAs use (current versus not current) 2.471 1.015 6.018 0.046
CCAs use (current versus not current) 1.585 0.560 4.490 0.386
BBs use (current versus not current) 1.108 0.335 3.660 0.867
Diuretics use (current versus not current) 2.195 1.018 4.732 0.045
Antidyslipidemic therapy (current versus not current) 0.934 0.430 2.029 0.863
Insulin therapy (current versus not current) 2.059 0.333 12.715 0.437
Oral antidiabetic therapy (current versus not current) 3.031 1.096 8.382 0.033
Diabetes mellitus 1.759 0.559 5.539 0.334
Arterial hypertension 1.460 0.671 3.180 0.340
ACEIs, angiotensin converter enzyme inhibitors; Apo, apolipoprotein; ARAs, angiotensin receptor antagonists; BBs, beta-blockers; BMI, body mass index;
BNP, brain natriuretic peptide; CCAs, calcium channel antagonists; CI, confidence interval; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate;
DAS, disease activity score; DKK-1, dickkopf-1; HAQ, health assessment questionnaire; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp(a),
lipoprotein (a); NSAIDs, nonsteroidal anti-inflammatory drugs; OPG, osteoprotegerin; OR, odds ratio; RANKL, receptor activator of nuclear factor-kappa B
ligand; TC, total cholesterol; TGs, triglycerides.
In early inflammatory polyarthritis,NT-proBNPhas been
associated with HAQ score and CRP [29] and this fact
may be indicative of the link between joint and cardiac
(myocardial and/or vascular) structural damage induced by
chronic inflammatory diseases.
In our RA patients, with a longer disease duration, BNP
was poorly correlated with HAQ (Spearman correlation; 𝑟 =
0.189, 𝑝 = 0.007), but levels superior to 100 pg/mL were
strongly associated with the presence of perfusion defects on
MPS independently of LV EF.
This result corroborates the hypothesis that MPS could
reveal subclinical cardiac dysfunction and supports the utility
of BNP measurement as a screening tool in the assessment
of CV risk in RA patients. This hypothesis needs to be
corroborated with further studies.
OPG and RANKL are bone-controlling cytokines of
mineral metabolism but also participate in the process of
atherogenesis, calcification, and plaque rupture at the vascu-
lar walls [30].
In vascular atherogenic remodeling process, OPG could
be increased due to a secondary compensatory mechanism
activation [31], and higher OPG serum levels have been asso-
ciated with coronary atherosclerosis [32], silent myocardial
ischemia, increasedCVmortality [33],myocardial infarction,
and heart failure prognosis [34].
By contrast, RANKL promotes calcification at the vascu-
lar wall and it has been mostly linked with the risk of plaque
instability and rupture [35].
In our study, we did not find associations between
myocardial perfusion defects with either RANKL or OPG
isolated levels, but rather with the highest quartile of the
distribution of the OPG/RANKL ratio. This elevated ratio
may be due to the presence of an ongoing vascular atheroscle-
rosis (high OPG) in a still stable and low-risk plaques (low
RANKL) in patients with abnormal MPS.
DKK-1 and sclerostin, two Wnt pathway inhibitors, are
also involved in the atherosclerosis process. DKK-1 is linked
not only with the effects of TNF𝛼 on joints in RA [36] but
also with platelet-mediated endothelial cell activation [13],
endothelial dysfunction in T2DM [37], vascular calcifica-
tion [38], and premature myocardial infarction [39]. DKK-
1 serum concentration has already been correlated with the
presence of coronary artery calcification and atherosclerosis
[40], and its measurement has been proposed as a simple
test that might be useful in CV risk stratification. Our results
corroborate this last hypothesis since we found a significant
association of DKK-1 levels with the presence of myocardial
perfusion defects.
The occurrence of few number of CV events in our
patients precludes statistical analysis for predictor variables
but significant reductions of cardiovascular events have been
reported with the use of biological compared with conven-
tional DMARDs in RA patients [41–43].
5. Study Limitations
The major limitation of this study is related with AC in
MPS which was not performed in all examinations and this
might have contributed to overestimating the prevalence of
perfusion defects in some patients; however, AC might also
introduce false-positive perfusion defects particularly among
the female population.
On the other hand, there was no coronary anatomy
control that can guarantee the atherosclerotic nature of all
perfusion defects nor the presence of balanced ischemia.
8 BioMed Research International
The low representativeness of male and early RA patients
precludes the extrapolation of obtained results to both gen-
ders and to patients with less disease duration.
6. Conclusions
A significant proportion of asymptomatic RA patients pre-
sented myocardial perfusion abnormalities in MPS. The
association with BNP, OPG/RANKL ratio, and DKK-1 levels
put in perspective the use of complementary approaches,
including serum biomarkers quantification in CV risk strat-
ification. Our results corroborated the hypothesis that MPS
could reveal subclinical cardiac dysfunction and supported
the utility of BNPmeasurement as a screening tool in CV risk
assessment of RA patients.
More studies are needed to definitely evaluate the utility
of different strategies (imaging, biomarkers) in the clinical
setting, particularly in the era of increasing availability of RA
biological therapies.
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